SecBot SecBot
Insider Cluster (3 insiders) ·Filed Nov 20, 2026

CRMD

CorMedix Inc.
BULLISH
Impact 5/10
Horizonweeks Processed1d 17h ago
Insider cluster: 3 insiders, $0.6M total
Actionable Insight ▲ Bullish

The cluster of open-market purchases by the CEO and two directors immediately after a revenue beat and material acquisition announcement suggests insider conviction in the near-term outlook. Monitor the Heron deal closing and REZZAYO sNDA decision in Q1 2027 as catalysts.

DirectionBullish
Confidencehigh
Horizonweeks

Drugs in focus

CRMD drug pipeline →

rezafungin

▲ Bullish Named in this insider cluster
Impact
Phase
Approved
Time to market
Already marketed (approved March 2023). The supplemental indication for prophylaxis has a PDUFA target in Q1 2027, with a promotional launch targeted for H2 2027 if approved.
Next catalyst
NDA filing · 2026

What to watchWatch for the specific PDUFA date announcement (Q1 2027) for the REZZAYO prophylaxis sNDA, which is the next major binary catalyst. The stock trades at ~$7.85 with ~$15.33 analyst target (95% upside) but carries ~20% short interest, suggesting a potential squeeze setup if the sNDA is approved. Monitor Q3 earnings on Nov 11, 2026 for REZZAYO revenue trajectory in the currently approved indications.

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Three CorMedix insiders, including CEO Joseph Todisco, made open-market purchases totaling $565K in the week following the Q3 2026 earnings release and the announced Heron asset acquisition. The CEO's $391K purchase is the largest, representing about 0.15% of market cap, and signals confidence after revenue beat and narrowed guidance.

Key Financial Metrics

Direction
buying
Total Value
$565.0K
Insiders
3

Key Facts

  • CEO Joseph Todisco purchased 80,000 shares at $4.89 for $391K on 2026-11-13
  • Director Myron Kaplan purchased 25,000 shares at $4.88 for $122K on 2026-11-16
  • Director Steven Lefkowitz purchased 11,500 shares at $4.53 for $52K on 2026-11-18
  • Total insider purchases of $565K represent 0.15% of $371M market cap
  • Q3 2026 consolidated revenue of $54.5M beat consensus of $51.2M
  • Company maintains FY2026 revenue guidance of $325-$345M and narrowed adjusted EBITDA guidance
  • Pending Heron Therapeutics asset acquisition expected to close Q1 2027
  • FDA accepted sNDA for REZZAYO prophylaxis indication with PDUFA in Q1 2027

Financial Impact

Insider purchases of $565K (0.15% of market cap) by CEO and two directors

market_capinsider_ownership

Risk Factors

  • Post-TDAPA DefenCath pricing headwinds continue; 2027 DefenCath guidance suspended
  • Heron acquisition requires stockholder approval and regulatory clearance
  • Revenue declined 48% YoY from $104.3M to $54.5M due to TDAPA transition

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-CRMD-1795199694745

Track record

24 reports on CRMD

Performance horizon

9 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +34.13% at T+60 after the Mar 5, 2026 report. 12 of 14 went positive at some point.

Filters
  1. Nov 20, 20261d ago Insider Cluster Bullish 5/10 Viewing Entry $5.28 Now $5.27 −0.09% settles Nov 30
  2. Nov 18, 20263d ago Insider Cluster Bullish 4/10 Entry $5.08 Now $5.27 +3.74% settles Nov 27
  3. Nov 13, 20268d ago DEFA14A / 8-K Bearish 6/10 Entry $4.82 Now $5.27 −9.34% settles Nov 23
  4. Nov 12, 202610d ago Press Release Bearish 5/10 Entry $4.84 to $5.08 Now $5.27 −8.88% ▼ −4.96% −10.41% vs SPY
  5. Nov 10, 202611d ago DEFA14A Neutral 6/10 Entry $5.30 to $4.50 Now $5.27 −0.57% ▼ −15.09% −11.20% vs SPY
  6. Nov 10, 202611d ago 8-K Bullish 7/10 Entry $5.30 to $4.50 Now $5.27 −0.57% ▼ −15.09% −11.20% vs SPY
  7. Nov 9, 202612d ago DEFA14A Neutral 6/10 Entry $5.47 to $4.82 Now $5.27 −3.66% ▼ −11.88% −10.19% vs SPY
  8. Nov 9, 202612d ago 8-K Neutral 6/10 Entry $5.47 to $4.82 Now $5.27 −3.66% ▼ −11.88% −10.19% vs SPY
  9. Nov 2, 202619d ago 8-K Neutral 5/10 No price data
  10. Nov 2, 202620d ago Press Release Neutral 4/10 Entry $5.39 to $5.47 Now $5.27 −2.23% ▲ +1.48% +1.41% vs SPY
Showing 10 of 24

US Market Status

Market Closed · Opens Mon (25h 58m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 20, 2026